Logo

Biogen’s Felzartamab Gains the US FDA’s Breakthrough Therapy Designation to Treat AMR in Kidney Transplant Recipients

Share this

Biogen’s Felzartamab Gains the US FDA’s Breakthrough Therapy Designation to Treat AMR in Kidney Transplant Recipients

Shots:

  • The US FDA has granted BTD to Felzartamab for treating late antibody-mediated rejection (AMR) without T-cell mediated rejection in kidney transplant individuals. The company anticipates a P-III study for felzartamab across AMR, IgAN, and PMN in 2025.
  • BTD approval was based on the data from the clinical development program that validated clinical proof of concept. This data was published in the NEJM and presented as a late-breaking presentation at the 61st ERA Congress in Stockholm, in May 2024.
  • Felzartamab is a human mAb under investigation that targets CD38, a protein shown in mature plasma cells, and P-II trials for Felzartamab have been completed in AMR, PMN, and IgAN. HI-Bio holds exclusive development & commercial rights of felzartamab across all indications globally excluding China; in July 2024 Biogen acquired HI-Bio

Ref: Biogen | Image: Biogen

Related News: HI-Bio Presents Positive Interim Data from P-II (IGNAZ) Trial of Felzartamab for IgAN at 61st ERA Congress 2024

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Dipanshu Dixit

A passionate content writer with expertise in delivering high-quality and engaging content, Dipanshu is a keen reader and a versatile writer. Dipanshu dedicatedly covers news ranging from biopharma, life sciences, biotech, and MedTech to diagnostics and animal health companies. He can be contacted at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions